# Developmental Therapeutics Research Program

> **NIH NIH P30** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $103,396

## Abstract

UWCCC Developmental Therapeutics (DT) Program Summary 
 Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang 
PROJECT SUMMARY/ABSTRACT 
The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to 
improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, 
and translating this research into early phase clinical trials. The DT Program provides the translational direction 
not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and 
resources inform our understanding of response and resistance mechanisms and enable the identification of 
new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core 
members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members 
are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer 
reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed 
non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 
publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic 
work). 
A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop 
Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the 
DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and 
biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical 
to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To 
this end, members of the DT Program come from basic science, applied science, and clinical departments. 
This program has expertise ranging from basic discovery (molecular pathways and targets), to development 
(drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and 
clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical 
trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific 
research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or 
participate in all clinical research groups facilitating both translational and reverse-translational opportunities.

## Key facts

- **NIH application ID:** 10147672
- **Project number:** 5P30CA014520-47
- **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON
- **Principal Investigator:** Christian Capitini
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $103,396
- **Award type:** 5
- **Project period:** 1997-04-25 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10147672

## Citation

> US National Institutes of Health, RePORTER application 10147672, Developmental Therapeutics Research Program (5P30CA014520-47). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10147672. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*